ClinConnect ClinConnect Logo
Search / Trial NCT01467401

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Launched by NOVO NORDISK A/S · Nov 4, 2011

Trial Information

Current as of June 03, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Type 2 diabetes for at least 24 months
  • Insulin treatment for the pase 3 months
  • HbA1c (glycosylated haemoglobin) below 13%
  • BMI (Body Mass Index) below 40 kg/m\^2
  • Ability and willingness to perform self-blood glucose monitoring
  • Exclusion Criteria:
  • Receipt of any investigational drug within 4 weeks prior to this trial
  • Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
  • Total daily insulin dosage less than or equal to 1.8 IU/kg

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.

Locations

örebro, , Sweden

Esbjerg, , Denmark

Næstved, , Denmark

Bergen, , Norway

Oslo, , Norway

århus C, , Denmark

Viborg, , Denmark

Malmö, , Sweden

Bekkestua, , Norway

Tromsø, , Norway

Karlstad, , Sweden

Värnamo, , Sweden

Mölndal, , Sweden

Grästorp, , Sweden

Holbæk, , Denmark

Silkeborg, , Denmark

Härnösand, , Sweden

Göteborg, , Sweden

Herning, , Denmark

Randers, , Denmark

Skive, , Denmark

Haugesund, , Norway

Hønefoss, , Norway

Moelv, , Norway

Vennesla, , Norway

åsgårdstrand, , Norway

Arvika, , Sweden

Avesta, , Sweden

Bjuv, , Sweden

Broby, , Sweden

Färgelanda, , Sweden

Habo, , Sweden

Helsingborg, , Sweden

Hässleholm, , Sweden

Jönköping, , Sweden

Kristianstad, , Sweden

Kristinehamn, , Sweden

Kungsbacka, , Sweden

Mellerud, , Sweden

Norrköping, , Sweden

Skövde, , Sweden

Stockholm, , Sweden

Säffle, , Sweden

Tomelilla, , Sweden

Torsby, , Sweden

Trollhättan, , Sweden

Tyresö, , Sweden

Uddevalla, , Sweden

östersund, , Sweden

Patients applied

0 patients applied

Trial Officials

Global Clinical Registry (GCR, 1452)

Study Director

Novo Nordisk A/S

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials